Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma
From the Servicios de Salud de Veracruz, Secretaría de Salud, Rio Blanco, Veracruz, Mexico
Verduzco-Rodriguez L, Aguirre-Gonzalez EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cel Ther 2011;4(4):182-184
Abstract
A 61-year-old male patient with metastatic poorly differentiated squamous cell carcinoma of larynx to lymph nodes and lung was treated with a third-line chemotherapy scheme with paclitaxel, nimotu zumab and low-dose methotrexate receiving a total of 30 cycles. The response was complete until today and maintained at 16 months. Nimotuzumab is a humanized mono clonal antibody used to treat squamous cell carcinomas of the head and neck. This third-line chemotherapy combination with pacli taxel-nimotuzumab-methotrexate seems to be an active combination and needs further clinical trials to validate its use in heavily treated patients.
Print version 
Plain text 
